Multi-Omic, Clinomic and Digitomic Attributes of Major Depression for Integrative Analytics

NCT ID: NCT05910957

Last Updated: 2025-08-03

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Total Enrollment: 40 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-08-02
• Study Completion Date: 2026-12-06

Brief Summary

The purpose of this research is to see if information from blood and data from smartwatches can be combined to help diagnose depression and determine if transitions between active depression and treated depression can be predicted.

Conditions

Major Depressive Disorder; Unipolar, Non-psychotic Major Depressive Disorder

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Non-depressed controls

Subjects without depression will fill out questionnaires about their general health and wellbeing, quality of life, mental health, emotional health, suicide risk, support system, and childhood experiences. Smartwatch data will also be collected to monitor step count, sleep quality, heart rate (resting and active), and activity rates.

No interventions assigned to this group

Antidepressant-treated adults

Subjects diagnosed with depression will fill out questionnaires about their general health and wellbeing, quality of life, mental health, emotional health, suicide risk, support system, and childhood experiences. Smartwatch data will also be collected to monitor step count, sleep quality, heart rate (resting and active), and activity rates.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Participated in the BROWNIE study.
• DSM-5 diagnostic criteria are met for unipolar, non-psychotic MDD (excluding controls).
• A score of > 10 on the QIDS-C and QIDS-SR (equivalent to 13 or greater on HAM-D17) given that when medication exceeds the effect of placebo in primary care participants have a HAM-D17 >12 (excluding controls).
• Antidepressant treatment is deemed appropriate by a study clinician (excluding controls).
• Smart watch wear time is at least 70% during their participation in the BROWNIE study.

Exclusion Criteria

• Subjects with medical contraindications that preclude treatment with study drugs will be excluded.
• Patients with schizophrenia, schizoaffective disorder, or who have bipolar I or II disorder (or another specified or unspecified bipolar spectrum disorder) will be excluded because they have a primary psychiatric condition that requires a different initial treatment.
• Subjects currently on antidepressant medication with subtherapeutic results in terms of depression management will undergo a medication taper and discontinuation prior to initiation of a new study medication. The subject will be closely monitored by the study clinician during the medication taper and discontinuation phase. The medication taper is left up to the study clinician's discretion. Study subjects who cannot be safely tapered from their medication or experience adverse effects during the taper will be excluded from the study.
• Subjects who have an active substance use disorder will be excluded. An active substance use disorder will be defined as meeting DSM-5 diagnostic criteria for any active substance use disorder. Persons meeting DSM-5 diagnostic criteria for a substance use disorder in full remission (>12 months) and a negative urine drug of abuse screen at the screening visit or before the baseline study visit will be considered eligible. Persons with a positive urine drug of abuse screen may participate in the study if they do not meet DSM-5 diagnostic criteria for a substance use disorder.
• Subjects unable to give informed consent or who are unwilling or unable to comply with study requirements are excluded.
• Pregnant subjects will be excluded.
• Subjects who are currently breastfeeding and who plan to continue breastfeeding will be excluded.
• Subjects who are psychiatrically hospitalized or in a mental health crisis requiring urgent care or psychiatric hospitalization.
• Study subjects currently on antipsychotic medications (e.g., typical, and atypical antipsychotic drugs) taken for primary psychotic illness or affective psychosis will be excluded.
• Study subjects taking mood stabilizing agents (e.g., lithium, carbamazepine, valproate, lamotrigine, gabapentin, or other anticonvulsants) taken specifically for bipolar spectrum disorders are not eligible for participation.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 62 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Florida State University

OTHER

Sponsor Role: collaborator

Mayo Clinic

OTHER

Sponsor Role: lead

Responsible Party

Mohit Chauhan, M.B.B.S.

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Mohit Chauhan, MBBS

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Mayo Clinic Florida

Jacksonville, Florida, United States

Countries

United States

Other Identifiers

23-002931

Identifier Type: -

Identifier Source: org_study_id